Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Innovotech Inc V.IOT

Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products.


TSXV:IOT - Post by User

Post by overnouton Mar 09, 2021 9:52am
209 Views
Post# 32751481

Insider Buying

Insider Buying

Vancouver, British Columbia –TheNewswire -March8,2021– Alan C. Savage, Chief Financial Officer and Director of  Innovotech Inc. (the “Issuer”) announces that he has, directly or indirectly, acquired an additional 1,586,555 common shares, 264,027 common share purchase warrants, and 35,000 stock options (collectively, the “Acquired Securities”).

As of October 23, 2019, the date of Mr. Savage’s previous early warning report, Mr. Savage had beneficial ownership of, or direction or control over, 11,401,000 Common Shares and 75,000 incentive stock options, representing approximately 31.5% of the then-issued and outstanding Common Shares on an undiluted basis (or approximately 31.6% of the then-issued and outstanding Common Shares on a partially diluted basis).

Following the acquisition of the Acquired Securities and the exercise of certain existing stock options, Mr. Savage has beneficial ownership of, or direction or control over, an aggregate of 13,062,555 common shares, 264,027 common share purchase warrants and 35,000incentive stock options, representing in the aggregate approximately 34.12% of the outstanding common shares of the Issuer on non-diluted basis (or  34.63% on a partially diluted basis). This represents an increase of 2.62% in Mr. Savage’s ownership of common shares on an undiluted basis (or an increase of 3.03% on a partially diluted basis) since the date of Mr. Savage’s previous early warning report.

These securities were acquired pursuant to various transactions, including market purchases through the facilities of the TSX Venture Exchange, purchases in the context of a private placement of units completed by the Issuer on September 2, 2020, a grant of incentive stock options made by the Issuer on October 16, 2020, issuances of common shares upon the exercise of existing incentive stock options, and as consideration for the assignment on February 19, 2021 by Lonsdale Capital Corporation (“Lonsdale”) to the Issuer of an 8% convertible debenture issued by CanBiocin Inc. with a principal amount outstanding of $150,000. Lonsdale is a corporation owned and controlled by Mr. Savage.

<< Previous
Bullboard Posts
Next >>